Kiora Pharmaceuticals Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • KPRX

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.55
  • (As of Friday Closing)

Kiora Pharmaceuticals General Information

Description

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Contact Information

Formerly Known As
Eyegate Pharmaceuticals, Inc., Optis France S.A
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 332 Encinitas Boulevard
  • Suite 102
  • Encinitas, CA 92024
  • United States
+1 (781) 000-0000

Kiora Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kiora Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.55 $0.53 $0.45 - $2.16 $14.3M 26.3M 216K -$1.12

Kiora Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 16,189 (1,365) 1,497 8,258
Revenue 16,000 0 0 0
EBITDA 2,592 (12,531) (13,703) (13,912)
Net Income 2,808 (12,514) (13,584) (13,771)
Total Assets 42,440 13,712 18,678 20,130
Total Debt 94 107 106 209
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kiora Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kiora Pharmaceuticals‘s full profile, request access.

Request a free trial

Kiora Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kiora Pharmaceuticals‘s full profile, request access.

Request a free trial

Kiora Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the trea
Drug Discovery
Encinitas, CA
12 As of 2023
00000
000000000 00000

000000

o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000 000000000
Watertown, MA
000 As of 0000
00000
00000000 00000

000000

, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Farmington Hills, MI
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kiora Pharmaceuticals Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EyePoint Pharmaceuticals Corporation Watertown, MA 000 00000 00000000 00000
Ocuphire Pharma Formerly VC-backed Farmington Hills, MI 00 00000 00000000 00000
Exonate Venture Capital-Backed Cambridge, United Kingdom 00 00.000 00000000000 00.000
Kodiak Sciences Formerly VC-backed Palo Alto, CA 000 00000 00000000 00000
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
You’re viewing 5 of 8 competitors. Get the full list »

Kiora Pharmaceuticals Patents

Kiora Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210299039-A1 Compositions and methods for treating ocular disease by contact lens mediated drug delivery Inactive 25-Mar-2020 0000000000 0
EP-4125813-A1 Compositions and methods for treating ocular disease by contact lens mediated drug delivery Pending 25-Mar-2020 0000000000
CA-3173160-A1 Compositions and methods for treating ocular disease by contact lens mediated drug delivery Pending 25-Mar-2020 0000000000
EP-4125812-A1 Compositions and methods for treatment of ocular conditions Pending 23-Mar-2020 0000000000
US-20210290527-A1 Compositions and methods for treatment of ocular conditions Pending 23-Mar-2020 A61K9/0048 0
To view Kiora Pharmaceuticals’s complete patent history, request access »

Kiora Pharmaceuticals Executive Team (12)

Name Title Board Seat Contact Info
Brian Strem Ph.D Chief Executive Officer & Board Member
Melissa Tosca Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Eric Daniels MD Chief Development Officer
Stefan Sperl Ph.D Executive Vice President CMC and Operations
You’re viewing 4 of 12 executive team members. Get the full list »

Kiora Pharmaceuticals Board Members (17)

Name Representing Role Since
Aron Shapiro Self Board Member 000 0000
Brian Strem Ph.D Kiora Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Carmine Stengone Self Board Member 000 0000
David Hollander Self Board Member 000 0000
Erin Parsons Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Kiora Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kiora Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kiora Pharmaceuticals‘s full profile, request access.

Request a free trial

Kiora Pharmaceuticals Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bayon Therapeutics 21-Oct-2021 0000000000 00000 Drug Discovery 00000 000
Panoptes Pharma 18-Dec-2020 0000000000 00.000 Drug Discovery 0000000 0
Jade Therapeutics 07-Mar-2016 Merger/Acquisition 00.000 Pharmaceuticals 0000000 0
To view Kiora Pharmaceuticals’s complete acquisitions history, request access »

Kiora Pharmaceuticals FAQs

  • When was Kiora Pharmaceuticals founded?

    Kiora Pharmaceuticals was founded in 1998.

  • Who is the CEO of Kiora Pharmaceuticals?

    Brian Strem Ph.D is the CEO of Kiora Pharmaceuticals.

  • Where is Kiora Pharmaceuticals headquartered?

    Kiora Pharmaceuticals is headquartered in Encinitas, CA.

  • What is the size of Kiora Pharmaceuticals?

    Kiora Pharmaceuticals has 12 total employees.

  • What industry is Kiora Pharmaceuticals in?

    Kiora Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Kiora Pharmaceuticals a private or public company?

    Kiora Pharmaceuticals is a Public company.

  • What is Kiora Pharmaceuticals’s stock symbol?

    The ticker symbol for Kiora Pharmaceuticals is KPRX.

  • What is the current stock price of Kiora Pharmaceuticals?

    As of 24-May-2024 the stock price of Kiora Pharmaceuticals is $0.55.

  • What is the current market cap of Kiora Pharmaceuticals?

    The current market capitalization of Kiora Pharmaceuticals is $14.3M.

  • What is Kiora Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Kiora Pharmaceuticals is $16M.

  • Who are Kiora Pharmaceuticals’s competitors?

    EyePoint Pharmaceuticals, Ocuphire Pharma, Exonate, Kodiak Sciences, and Kymab are some of the 8 competitors of Kiora Pharmaceuticals.

  • What is Kiora Pharmaceuticals’s annual earnings per share (EPS)?

    Kiora Pharmaceuticals’s EPS for 12 months was -$1.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »